非布司他治疗效果好吗？

It is the latest XOR inhibitor developed in the world. It acts on this oxidase highly selectively, reducing the synthesis of uric acid in the body and lowering the concentration of uric acid, thereby effectively treating ventilation diseases. Indications of Febuxostat: Clinically used for gout and gouty nephropathy. This product is effective for patients who are ineffective or intolerant to drugs that promote uric acid excretion. Not recommended for use in asymptomatic hyperuricemia. So is febuxostat effective in treating gout?

Febuxostat is very effective in reducing uric acid in the human body, and the effect is very fast. After taking febuxostat, uric acid can be reduced to an ideal value. When using febuxostat to reduce uric acid in the human body, the dosage can be appropriately reduced according to the specific situation. However, it must be reduced under the guidance and supervision of a doctor, and it cannot be increased or decreased without permission, otherwise it will cause great harm to the body. 

A phase III clinical trial compared the efficacy of this product (80 and 120 mg/d) with that of allopurinol (300 mg/d). A 1-year study of 760 patients showed that compared with the allopurinol group, more patients in the this product group achieved the main trial efficacy indicator - the sUA concentration was measured below 60 mg/L in the last 3 months (all subjects were gout patients, and the sUA concentration before the test were all above 80 mg/L); after 52 weeks of treatment, this product failed to significantly reduce the area of tophi (tophi is unique to gout) aggregates of urate crystals), but in the high-dose group in the early stages of the trial, this effect was more obvious; in each treatment group, patients with sUA concentrations reaching the target (<60 mg/L) were less likely to have gout attacks, and their tophi area was more significantly reduced; adverse reactions and their incidence rates were similar in each treatment group, including abnormal liver function, diarrhea, headache, joint-related signs and symptoms, and musculoskeletal/connective tissue symptoms.

Febuxostat can be used in combination with other drugs, such as colchicine (0.6 mg twice a day), certain non-steroidal anti-inflammatory drugs (naproxen, indomethacin, etc.), hydrochlorothiazide, warfarin, desimipramine, etc., without significant impact on the pharmacokinetics of the two, and no dose adjustment is required. However, it is currently not recommended to use febuxostat in combination with azathioprine and mercaptopurine because the latter two are metabolized by xanthine oxidase.  

Research results show that long-term use of febuxostat can maintain long-term blood uric acid in most patients at ≤6.0 mg/dl. Mild to moderate impairment of renal function has no significant impact on the pharmacodynamics and pharmacokinetics of febuxostat. Therefore, the uric acid-lowering effect of febuxostat is no different from that of patients with normal renal function, and its safety is good. In short, the uric acid-lowering effect is better than that of allopurinol without serious adverse reactions, and it has good clinical application prospects.